COVID-19 neutralising antibody test, AbC-19, available to CLIA testing labs in the USA following the completion of FDA Section IV.D by Abingdon Health
Abingdon Health announces the appointment of Mary Tavener as Non-Executive Director (NED) and Board member with immediate effect. Mary will be the Senior...
Abingdon Health announces £1M Innovate UK funding for the development of a fully quantitative lateral flow Smartphone Reader Innovate UK has released £1M...
Abingdon Health, the lead in the UK-Rapid Test Consortium (UK-RTC), achieves CE marking for AbC-19 Rapid Test.
Abingdon Health is delighted to announce the UK-RTC has reached design freeze for the AbC-19TM lateral flow test for IgG antibodies to the...
Professor Mike Holmes appointed as a medical advisor to support Abingdon Health’s work on developing SARS-CoV-2 rapid tests.
Abingdon Health appoints Lyn Rees as non-executive director and board member.
Investment in state-of-the-art automation cements Abingdon Health’s position as a leading global rapid test manufacturer
Professor Lawrence S. Young appointed as a scientific advisor to support Abingdon Health’s work on developing SARS-CoV-2 rapid tests.
Abingdon Health announces expansion via the acquisition of Concepta plc’s Doncaster facility
UK lateral flow rapid test manufacturer, Abingdon Health, confirms expansion at its York site